Folic Acid-Conjugated CuFeSe2 Nanoparticles for Targeted T2-Weighted Magnetic Resonance Imaging and Computed Tomography of Tumors In Vivo

Assessment of CuFeSe2 ternary nanozymes for multimodal triple negative breast cancer theranostics

Triple negative breast cancer (TNBC) remains a challenge for clinical diagnosis and therapy due to its poor prognosis and high mortality rate. Hence, new methods to achieve TNBC imaging and imaging-guided TNBC therapy are urgently needed. Currently, the combination of chemotherapy with phototherapy/catalytic therapy has become a promising strategy for cancer treatment. Here, multifunctional CuFeSe2 ternary nanozymes (CuFeSe2-AMD3100-Gem nanosheets) were prepared as high-performance nanotheranostic agents for imaging-guided synergistic therapy of TNBC in vitro and in vivo. CuFeSe2-AMD3100-Gem nanosheets not only exhibited outstanding CXCR4-targeted capability and superior photothermal properties, but also produced exact chemical cytotoxicity through the loading of the chemotherapy drug Gemcitabine. Specifically, the CuFeSe2-AMD3100-Gem nanosheets simultaneously possessed peroxidase-like activities capable of converting endogenous H2O2 to hydroxyl radicals (•OH), which could be significantly enhanced under light irradiation. Furthermore, these nanosheets showed remarkable multimodal imaging ability for magnetic resonance imaging (MRI), computed tomography (CT) and infrared thermography in TNBC tumor-bearing mice (4T1 cells). More importantly, the in vitro and in vivo results verified the significant synergistic anticancer effect of the CuFeSe2-AMD3100-Gem nanosheets by combining photothermal therapy and enzyme catalytic therapy with chemotherapy. In conclusion, these advantages demonstrate the powerful potential of CuFeSe2 ternary nanozymes for imaging-guided synergistic photothermal/catalytic/chemical therapy for TNBC.

Construction of CXCR4 Receptor-Targeted CuFeSe2 Nano Theranostic Platform and Its Application in MR/CT Dual Model Imaging and Photothermal Therapy

Introduction

Targeting, imaging, and treating tumors represent major clinical challenges. Developing effective theranostic agents to address these issues is an urgent need.

Methods

We introduce an "all-in-one" tumor-targeted theranostic platform using CuFeSe2-based composite nanoparticles (CuFeSe2@PA) for magnetic resonance (MR) and computed tomography (CT) dual model imaging-guided hyperthermia tumor ablation. Plerixafor (AMD3100) is bonded to the surface of CuFeSe2 as a targeting unit. Due to the robust interaction between AMD3100 and the overexpressed Chemokine CXC type receptor 4 (CXCR4) on the membrane of 4T1 cancer cells, CuFeSe2@PA specifically recognizes 4T1 cancer cells, enriching the tumor region.

Results

CuFeSe2@PA serves as a contrast agent for T2-weighted MR imaging (relaxivity value of 1.61 mM-1 s-1) and CT imaging. Moreover, it effectively suppresses tumor growth through photothermal therapy (PTT) owing to its high photothermal conversion capability and stability, with minimized side effects demonstrated both in vitro and in vivo.

Discussion

CuFeSe2@PA nanoparticles show potential as dual-mode imaging contrast agents for MR and CT and provide an effective means of tumor treatment through photothermal therapy. The surface modification with Plerixafor enhances the targeting ability of the nanoparticles, performing more significant efficacy and biocompatibility in the 4T1 cancer cell model. The study demonstrates that CuFeSe2@PA is a promising multifunctional theranostic platform with clinical application potential.

Hybrid FeWO4-Hyaluronic Acid Nanoparticles as a Targeted Nanotheranostic Agent for Multimodal Imaging-Guided Tumor Photothermal Therapy

Background

Development of versatile nanoplatform still remains a great challenge due to multistep synthesis and complicated compositions. Therefore, it is significant to develop a facile method to synthesize a nanocomposite to achieve multimodal imaging and even imaging-guided cancer therapeutics.

Methods and Results

In our study, hyaluronic acid-functionalized iron (II) tungstate nanoparticles (HA-FeWO4 NPs) were successfully synthesized as a versatile nanoplatform by a facile one-pot hydrothermal procedure. The formed multifunctional HA-FeWO4 NPs were investigated via a series of characterization techniques, which demonstrated good biocompatibility, excellent dispersion, low cytotoxicity, active tumor-targeting ability and high photothermal efficiency. Furthermore, tumor was clearly visualized by HA-FeWO4 NPs with multimodal imaging of infrared thermal imaging, magnetic resonance imaging, computed tomography imaging in 4T1 tumor bearing mice. More importantly, HA-FeWO4 could achieve multimodal imaging-guided photothermal therapy of 4T1 tumors.

Conclusion

The constructed HA-FeWO4 NPs have great potential as ideal nanotheranostic agents for multimodal imaging and even imaging-guided cancer theranostics in biological systems.

Metal selenide nanomaterials for biomedical applications

Metal selenide nanomaterials have received enormous attention as they possess diverse compositions, microstructures, and properties. The combination of selenium with various metallic elements gives the metal selenide nanomaterials distinctive optoelectronic and magnetic properties, such as strong near-infrared absorption, excellent imaging properties, good stability, and long in vivo circulation. This makes metal selenide nanomaterials advantageous and promising for biomedical applications. This paper summarizes the research progress in the last five years in the controlled synthesis of metal selenide nanomaterials in different dimensions and with different compositions and structures. Then we discuss how surface modification and functionalization strategies are well-suited for biomedical fields, including tumor therapy, biosensing, and antibacterial biological applications. The future trends and issues of metal selenide nanomaterials in the biomedical field are also discussed.

Nanomaterial-based CT contrast agents and their applications in image-guided therapy

Computed tomography (CT), a diagnostic tool with clinical application, comprehensive coverage, and low cost, is used in hospitals worldwide. However, CT imaging fails to distinguish soft tissues from normal organs and tumors because their mass attenuation coefficients are similar. Various CT contrast agents have been developed in recent years to improve the sensitivity and contrast of imaging. Here, we review the progress of nanomaterial-based CT contrast agents and their applications in image-guided therapy. The CT contrast agents are classified according to their components; gold (Au)-based, bismuth (Bi)-based, lanthanide (Ln)-based, and transition metal (TM)-based nanomaterials are discussed. CT image-guided therapy of diseases, including photothermal therapy (PPT), photodynamic therapy (PDT), chemotherapy, radiotherapy (RT), gas therapy, sonodynamic therapy (SDT), immunotherapy, starvation therapy, gene therapy (GT), and microwave thermal therapy (MWTT), are reviewed. Finally, the perspectives on the CT contrast agents and their biomedical applications are discussed.

Targeted Molecular Imaging Probes Based on Magnetic Resonance Imaging for Hepatocellular Carcinoma Diagnosis and Treatment

Hepatocellular carcinoma (HCC) is the sixth most commonly malignant tumor and the third leading cause of cancer-related death in the world, and the early diagnosis and treatment of patients with HCC is core in improving its prognosis. The early diagnosis of HCC depends largely on magnetic resonance imaging (MRI). MRI has good soft-tissue resolution, which is the international standard method for the diagnosis of HCC. However, MRI is still insufficient in the diagnosis of some early small HCCs and malignant nodules, resulting in false negative results. With the deepening of research on HCC, researchers have found many specific molecular biomarkers on the surface of HCC cells, which may assist in diagnosis and treatment. On the other hand, molecular imaging has progressed rapidly in recent years, especially in the field of cancer theranostics. Hence, the preparation of molecular imaging probes that can specifically target the biomarkers of HCC, combined with MRI testing in vivo, may achieve the theranostic purpose of HCC in the early stage. Therefore, in this review, taking MR imaging as the basic point, we summarized the recent progress regarding the molecular imaging targeting various types of biomarkers on the surface of HCC cells to improve the theranostic rate of HCC. Lastly, we discussed the existing obstacles and future prospects of developing molecular imaging probes as HCC theranostic nanoplatforms.